Trials / Terminated
TerminatedNCT00611637
CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease
A Pilot Clinical Trial of CMV pp65 Specific T Cell Adoptive Immunotherapy in Patients Who Have Undergone Allogeneic Stem Cell Transplantation for Malignant Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- H. Kim Lyerly · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and feasibility of CMV specific, T cell adoptive immunotherapy in patients who have undergone allogeneic stem cell transplantation for malignant disease.
Detailed description
The primary purpose of this clinical trial is to evaluate the safety of this treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CMV pp65 Specific T Cells | Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes. |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2008-02-01
- Completion
- 2008-06-01
- First posted
- 2008-02-11
- Last updated
- 2012-11-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00611637. Inclusion in this directory is not an endorsement.